{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:54:12Z","timestamp":1762865652252},"reference-count":163,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1586\/ern.10.38","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T14:23:27Z","timestamp":1272291807000},"page":"791-809","source":"Crossref","is-referenced-by-count":34,"title":["Treating multiple sclerosis with monoclonal antibodies: a 2010 update"],"prefix":"10.1586","volume":"10","author":[{"given":"Mathias","family":"Buttmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.3.433"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.0b013e3181bd114f","volume":"73","author":"Zecca","year":"2009","journal-title":"Neurology"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181beed38","volume":"73","author":"Stuve","year":"2009","journal-title":"Neurology"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0b013e3181cef810","volume":"74","author":"Gutwinski","year":"2010","journal-title":"Neurology"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"Egli","year":"2009","journal-title":"J. Infect. Dis."},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10450"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.080708.082655"},{"key":"CIT0008","unstructured":"Rudick RA, Polman CH, O\u2019Connor PWet al.Evaluation of natalizumab treatment on the presence of JC virus in blood and urine from multiple sclerosis patients. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9\u201312 September 2009 (P883)."},{"key":"CIT0009","unstructured":"Dominguez-Mozo MI, Alvarez-Lafuente R, Garcia-Montojo Met al.JC virus in multiple sclerosis patients treated with natalizumab. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.Duesseldorf, Germany, 9\u201312 September 2009 (P315)."},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMc0909622","volume":"361","author":"Gorelik","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904267"},{"key":"CIT0012","author":"Sadiq","year":"2009","journal-title":"J. Neurol."},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70078-9"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1086\/504947"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","volume":"73","author":"Marzocchetti","year":"2009","journal-title":"Neurology"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh215"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4049\/jimmunol.168.1.499","volume":"168","author":"Koralnik","year":"2002","journal-title":"J. Immunol."},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70006-5"},{"key":"CIT0019","unstructured":"Haghikia A, Pappas D, Pula Bet al.Assessment of a possible bioenergetic marker of cellular immunocompetence in MS patients undergoing immunotherapy: longitudinal analyses. Presented at:61st Annual Meeting of the American Academy of Neurology. Seattle, USA, 25 April\u20132 May 2009."},{"key":"CIT0020","unstructured":"Varnier OE, McDermott JL, Giacomazzi CGet al.Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifies two PML cases in HIV and congenital immunodeficiency patients. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9\u201312 September 2009 (P889)."},{"key":"CIT0021","first-page":"590","volume":"56","author":"Schulick","year":"1993","journal-title":"Transplantation"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1399-0012.2003.00013.x","volume":"17","author":"Kowalski","year":"2003","journal-title":"Clin. Transplant."},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum."},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.10827","volume":"55","author":"d\u2019Arminio Monforte","year":"2004","journal-title":"Ann. Neurol."},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","volume":"199","author":"Engsig","year":"2009","journal-title":"J. Infect. Dis."},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00019052-200406000-00019","volume":"17","author":"Koralnik","year":"2004","journal-title":"Curr. Opin. Neurol."},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-1-78"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1086\/315817","volume":"182","author":"De Luca","year":"2000","journal-title":"J. Infect. Dis."},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13550280390195388","volume":"9","author":"Antinori","year":"2003","journal-title":"J. Neurovirol."},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0303","volume":"2","author":"Riedel","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"CIT0031","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1212\/01.wnl.0000343854.80344.69","volume":"72","author":"McCombe","year":"2009","journal-title":"Neurology"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2009.11.013","volume":"219","author":"Sidhu","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"CIT0033","unstructured":"Perumal J, Hreha S, Bao Fet al.Post-natalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI findings. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9\u201312 September 2009 (P418)."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810316"},{"key":"CIT0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","volume":"361","author":"Wenning","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.07.006"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782"},{"key":"CIT0041","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"CIT0042","unstructured":"O\u2019Connor PW, Polman CH, Goodman ADet al.Efficacy and safety of natalizumab in the STRATA study. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.Duesseldorf, Germany, 9\u201312 September 2009."},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327341.89587.76"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1212\/01.wnl.0000341783.33962.5b","volume":"72","author":"Schiess","year":"2009","journal-title":"Neurology"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.466"},{"key":"CIT0047","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0029-1220429","volume":"36","author":"Gold","year":"2009","journal-title":"Aktuelle Neurologie"},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/QAD.0b013e32830a5043","volume":"22","author":"De Luca","year":"2008","journal-title":"Aids"},{"key":"CIT0049","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/13550289809114545","volume":"4","author":"Hou","year":"1998","journal-title":"J. Neurovirol."},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"Hall","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-08"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1126\/science.1103492"},{"key":"CIT0053","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virusres.2007.11.002","volume":"132","author":"O\u2019Hara","year":"2008","journal-title":"Virus Res."},{"key":"CIT0054","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1086\/431769","volume":"41","author":"Lima","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"CIT0055","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1086\/520514","volume":"196","author":"Verma","year":"2007","journal-title":"J. Infect. Dis."},{"key":"CIT0056","author":"Bezabeh","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"CIT0057","first-page":"1476","volume":"89","author":"Golay","year":"2004","journal-title":"Haematologica"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404014"},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13693780400007151","volume":"46","author":"Smolewski","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.05.014"},{"key":"CIT0061","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.200535075","volume":"35","author":"Cox","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"CIT0062","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"Thompson","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"CIT0063","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1084\/jem.192.10.1453","volume":"192","author":"Batten","year":"2000","journal-title":"J. Exp. Med."},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x"},{"key":"CIT0065","unstructured":"Wray S. A descriptive analysis of infectious adverse events in alemtuzumab-treated multiple sclerosis patients. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. D\u00fcsseldorf, Germany, 9\u201312 September 2009 (P812)."},{"key":"CIT0066","first-page":"77","volume":"16","author":"Jones","year":"2009","journal-title":"Int. MS J."},{"key":"CIT0067","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.md.0000159082.45703.90","volume":"84","author":"Chen","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"CIT0068","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beha.2006.09.008","volume":"20","author":"Daikeler","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"CIT0069","first-page":"4254","volume":"85","author":"Jubault","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"CIT0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2006.04.569","volume":"120","author":"Krupica","year":"2006","journal-title":"Clin. Immunol."},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.098400"},{"key":"CIT0072","first-page":"2052","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Invest."},{"key":"CIT0073","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.beem.2009.07.003","volume":"23","author":"Weetman","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670"},{"key":"CIT0075","unstructured":"Coles AJ. Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. D\u00fcsseldorf, Germany, 9\u201312 September 2009."},{"key":"CIT0076","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00415-008-0696-y","volume":"255","author":"Hirst","year":"2008","journal-title":"J. Neurol."},{"key":"CIT0077","unstructured":"Selmaj K. Immunogenicity of alemtuzumab treatment for relapsing\u2013remitting multiple sclerosis: no effect on efficacy or safety. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. D\u00fcsseldorf, Germany, 9\u201312 September 2009 (P811)."},{"key":"CIT0078","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaut.2008.04.005","volume":"31","author":"Ooi","year":"2008","journal-title":"J. Autoimmun."},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0934-5"},{"key":"CIT0080","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/j.1468-1331.2009.02552.x","volume":"16","author":"Pace","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"CIT0083","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann. Neurol."},{"key":"CIT0084","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2009.04.019","volume":"286","author":"Wolinsky","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21363"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"CIT0087","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"CIT0088","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1749-6632.2009.04871.x","volume":"1173","author":"Cayrol","year":"2009","journal-title":"Ann. NY Acad. Sci."},{"key":"CIT0089","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","volume":"386","author":"Kinoshita","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159399.81861.D5"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.11.noc80069"},{"key":"CIT0092","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14712590903018837","volume":"9","author":"Kausar","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"CIT0093","first-page":"251","volume":"67","author":"van Meerten","year":"2009","journal-title":"Neth. J. Med."},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1002\/art.23732"},{"key":"CIT0095","doi-asserted-by":"crossref","first-page":"199A","DOI":"10.1182\/blood-2007-01-068056","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03166.x"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902832679"},{"key":"CIT0098","first-page":"294","volume":"10","author":"Robak","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"CIT0100","first-page":"2062","volume":"66","author":"Traynor","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"CIT0102","unstructured":"Ostergaard M, Baslund B, Rigby Wet al.Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: early results from an ongoing, double-blind, randomized, placebo-controlled clinical trial. Presented at:ACR\/ARHP 2007 Annual Scientific Meeting. Boston, USA, 6\u201311 November 2007."},{"key":"CIT0103","unstructured":"Ostergaard M, Baslund B, Rigby Wet al.Efficacy of ofatumumab in rheumatoid arthritis (RA) patients with inadequate response to one or more DMARDS: 48 weeks follow-up. Presented at:ACR\/ARHP 2008 Annual Scientific Meeting. San Francisco, CA, USA, 24\u201329 October 2008."},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"CIT0105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"CIT0106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900632"},{"key":"CIT0107","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1349-7006.2009.01392.x","volume":"101","author":"Uchiyama","year":"2009","journal-title":"Cancer Sci."},{"key":"CIT0108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1761"},{"key":"CIT0109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06916.x"},{"key":"CIT0110","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"CIT0111","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601335103"},{"key":"CIT0112","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70033-8"},{"key":"CIT0113","unstructured":"Sheridan J, Elkins J, Zhang Yet al.Expansion of CD56bright NK cells correlates with therapeutic response to daclizumab in multiple sclerosis. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. D\u00fcsseldorf, Germany, 9\u201312 September 2009 (P430)."},{"key":"CIT0114","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.16"},{"key":"CIT0115","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031579"},{"key":"CIT0116","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/eji.200526065","volume":"35","author":"Haas","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"CIT0117","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.50"},{"key":"CIT0118","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1352458508097468","volume":"15","author":"Ali","year":"2009","journal-title":"Mult. Scler."},{"key":"CIT0119","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003495-200969090-00001","volume":"69","author":"Chien","year":"2009","journal-title":"Drugs"},{"key":"CIT0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"key":"CIT0121","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.10.007"},{"key":"CIT0122","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"CIT0123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"CIT0124","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355"},{"key":"CIT0125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257"},{"key":"CIT0126","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1084\/jem.187.4.537","volume":"187","author":"Segal","year":"1998","journal-title":"J. Exp. Med."},{"key":"CIT0127","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.771"},{"key":"CIT0128","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.2.599"},{"key":"CIT0129","doi-asserted-by":"crossref","first-page":"7768","DOI":"10.4049\/jimmunol.176.12.7768","volume":"176","author":"Vaknin-Dembinsky","year":"2006","journal-title":"J. Immunol."},{"key":"CIT0130","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-500"},{"key":"CIT0131","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1043-4666(05)80008-0","volume":"5","author":"Woodroofe","year":"1993","journal-title":"Cytokine"},{"key":"CIT0132","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70173-X"},{"key":"CIT0133","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.3.319"},{"key":"CIT0134","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"CIT0135","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.4049\/jimmunol.0800933","volume":"183","author":"Khan","year":"2009","journal-title":"J. Immunol."},{"key":"CIT0136","unstructured":"Kikly K, Manetta J, Smith H, Wierda D, Witcher D. Characterization of LY2127399, a neutralizing antibody for BAFF. Presented at:ACR\/ARHP 2009 Annual Scientific Meeting. PA, USA, 17\u201321 October 2009."},{"key":"CIT0137","unstructured":"Genovese MC, Mociran E, Biagini M, Bojin S, Sloan-Lancaster J. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). Presented at:ACR\/ARHP 2009 Annual Scientific Meeting. PA, USA, 17\u201321 October 2009."},{"key":"CIT0138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jneuroim.2003.10.056","volume":"148","author":"Magliozzi","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"CIT0139","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/intimm\/dxl080","volume":"18","author":"Huntington","year":"2006","journal-title":"Int. Immunol."},{"key":"CIT0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J. Exp. Med."},{"key":"CIT0141","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000082106","volume":"8","author":"Mackay","year":"2005","journal-title":"Curr. Dir. Autoimmun."},{"key":"CIT0142","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2004.03.017","volume":"152","author":"Thangarajh","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"CIT0143","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","volume":"131","author":"Krumbholz","year":"2008","journal-title":"Brain"},{"key":"CIT0144","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archneur.1997.00550210095020","volume":"54","author":"Schwid","year":"1997","journal-title":"Arch. Neurol."},{"key":"CIT0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03343730","volume":"23","author":"Rotondi","year":"2000","journal-title":"J. Endocrinol. Invest."},{"key":"CIT0146","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2326"},{"key":"CIT0147","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509347154"},{"key":"CIT0148","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00415-009-5200-9","volume":"256","author":"Ismail","year":"2009","journal-title":"J. Neurol."},{"key":"CIT0149","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMc0706103","volume":"358","author":"Mullen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"CIT0150","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21782"},{"key":"CIT0151","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s10072-009-0142-7","volume":"30","author":"Martinelli","year":"2009","journal-title":"Neurol. Sci."},{"key":"CIT0152","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267662.41734.1f"},{"key":"CIT0153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"CIT0154","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"CIT0155","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"CIT0156","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.5.6.721"},{"key":"CIT0157","doi-asserted-by":"crossref","unstructured":"Cook S, Vermersch P, Comi Get al.Safety and tolerability of cladribine tablets in relapsing\u2013remitting multiple sclerosis during the 96-week, Phase III, double-blind, placebo-controlled CLARITY study. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9\u201312 September 2009.","DOI":"10.1016\/S0022-510X(09)70788-9"},{"key":"CIT0158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052643"},{"key":"CIT0159","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"CIT0160","unstructured":"Freedman M, Wolinsky JS, Byrnes WJet al.Oral Teriflunomide or placebo added to interferon \u03b2 for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Presented at:25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9\u201312 September 2009."},{"key":"CIT0161","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60918-6"},{"key":"CIT0162","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61619-0"},{"key":"CIT0163","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b9c8f7"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/ern.10.38","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:03:50Z","timestamp":1559070230000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/ern.10.38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":163,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,1,9]]},"published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1586\/ern.10.38"],"URL":"https:\/\/doi.org\/10.1586\/ern.10.38","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}